Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18

Section 28

Good clinical practices

Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 28 · current to July 24, 2025 · regulation last amended February 27, 2022

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

A holder of a COVID-19 drug authorization must ensure that the clinical trial for which the authorization has been issued is conducted in accordance with good clinical practices and, without limiting the generality of the foregoing, must ensure that (a) the clinical trial is scientifically sound and clearly described in the protocol; (b) the clinical trial is conducted, and the drug is used, in accordance with the protocol and these Regulations; (c) systems and procedures that assure the quality of every aspect of the clinical trial are implemented; (d) for each clinical trial site, the approval of a research ethics board is obtained before the clinical trial begins; (e) at each clinical trial site, there is no more than one qualified investigator; (f) at each clinical trial site, medical care and medical decisions, in respect of the clinical trial, are under the supervision of a health care professional who is authorized to provide medical care and make medical decisions; (g) each person who is involved in the conduct of the clinical trial is qualified by education, training and experience to perform their respective tasks; (h) informed consent, given in accordance with the applicable laws governing consent, is obtained from every person before they participate in the clinical trial, but only after that person has been informed of (i) the risks and anticipated benefits to their health arising from participation in the clinical trial, and (ii) all other aspects of the clinical trial that are necessary for that person to make the decision to participate in the clinical trial; and (i) the drug is manufactured, handled and stored in accordance with the applicable good manufacturing practices referred to in Divisions 2 and 4 of Part C of the Food and Drug Regulations, with the exception of sections C.02.019, C.02.025 and C.02.026 of those Regulations.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.